Cardiac manifestations of neonatal lupus erythematosus: Guidelines to management, integrating clues from the bench and bedside

Nature Clinical Practice Rheumatology

Volumn 5, Issue 3, 2009, Pages 139-148

  Buyon, Jill P ^a   Clancy, Robert M ^b   Friedman, Deborah M ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BETAMETHASONE; DEXAMETHASONE; IMMUNOGLOBULIN G; LA ANTIBODY; MATERNAL ANTIBODY; RO ANTIBODY;

ADRENAL SUPPRESSION; BETA ADRENERGIC STIMULATION; BLOOD PLACENTA BARRIER; BRADYCARDIA; BRAIN GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONGENITAL HEART BLOCK; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DYSLEXIA; FETAL THERAPY; FIRST DEGREE ATRIOVENTRICULAR BLOCK; HEART DISEASE; HEART MUSCLE NECROSIS; HIGH RISK PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; INTRAUTERINE GROWTH RETARDATION; LEARNING DISORDER; LIVE BIRTH; LUPUS ERYTHEMATOSUS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEWBORN LUPUS ERYTHEMATOSUS; OLIGOHYDRAMNIOS; PATHOGENESIS; PR INTERVAL; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SURVIVAL RATE;

AUTOANTIBODIES; ELECTROCARDIOGRAPHY; FEMALE; FETAL DISEASES; HEART BLOCK; HEART DEFECTS, CONGENITAL; HUMANS; IMMUNOGLOBULIN G; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFUSIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; RIBONUCLEOPROTEINS; RISK FACTORS;

EID: 62849120598     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum1018     Document Type: Review

References (46)

1. Buyon JP et al. (1996) The effects of pregnancy on autoimmune diseases. Clin Immunol Immunopath 78: 99-104
2. Buyon JP and Clancy RM (2006) Neonatal lupus. In Dubois' Lupus Erythematosus, edn 7, 1058-1080 (Eds Wallace DJ and Hahn BH) Philadelphia: Lippincott Williams & Wilkins
3. Leach JL et al. (1996) Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol 157: 3317-3322
4. Jaeggi ET et al. (2002) Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. J Am Coll Cardiol 39: 130-137
5. Moak JP et al. (2001) Congenital heart block: Development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 37: 238-242
6. Buyon JP et al. (1998) Autoimmune-associated congenital heart block: Mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 31: 1658-1666
7. Waltuck J and Buyon J (1994) Autoantibody-associated congenital heart block: Outcome in mothers and children. Annals Int Med 120: 544-551
8. Brucato A et al. (2001) Risk of congenital heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis. Arthritis Rheum 44: 1832-1835
9. Friedman DM et al. (2008) Utility of cardiac monitoring in fetuses at risk for congenital heart block: The PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 117: 485-493
10. Salomonsson S et al. (2002) A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 46: 1233-1241
11. Salomonsson S et al. (2005) Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 201: 11-17
12. Buyon JP et al. (1994) Autoantibody responses to the "native" 52 kDa SS-A/Ro protein in neonatal lupus syndromes, systemic lupus erythematosus and Sjögren's syndrome. J Immunology 152: 75-84
13. Clancy RM et al. (2005) Maternal antibody responses to the 52 kDa SSA/Ro p200 peptide and the development of fetal conduction defects. Arthritis Rheum 52: 3079-3086
14. Solomon DG et al. (2003) Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: Implications for pathogenesis and family counseling. Lupus 12: 646-647
15. Gordon P et al. (2004) Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheum 31: 2480-2487
16. Vincent A et al. (2000) Molecular targets for autoimmune and genetic disorders of neuromuscular transmission. Eur J Biochem 267: 6717-6728
17. Kreier JP (2002) Infection, Resistance and Immunity, edn 2. Oxford, UK: Taylor & Francis
18. Alexander E et al. (1992) Anti-Ro/SS-A antibodies in the pathophysiology of congenital heart block in neonatal lupus syndrome, an experimental model: in vitro electrophysiologic and immunocytochemical studies. Arthritis Rheum 35: 176-189
19. Garcia S et al. (1994) Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 93: 718-724
20. Boutjdir M et al. (1998) Serum and IgG from the mother of a child with congenital heart block induce conduction abnormalities and inhibit L-type calcium channels in a rat heart model. Pediatr Res 80 354-362
21. 4 serotoninergic receptors, 52 kD SSA/Ro and autoimmune-associated congenital heart block. J Autoimmunity 19: 79-86
22. 4 receptor and congenital heart block: A reassessment. J Autoimmun 25: 72-76
23. Clancy RM et al. (2004) Immunohistologic evidence supports apoptosis, IgG deposition and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. Arthritis Rheum 50: 173-182
24. Clancy RM et al. (2006) Impaired clearance of apoptotic cardiocytes linked to anti-SSA/Ro-SSB/La antibodies in pathogenesis of congenital heart block. J Clin Investigation 116: 2413-2422
25. Clancy RM et al. (2002) Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol 169:2156-2163
26. Miranda-Carús ME et al. (2000) Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of tumor necrosis factor a by macrophages. J Immunol 165: 5345-5351
27. Clancy RM et al. (2003) Cytokine polymorphisms and histologic expression in autopsy studies: Contribution of TNF-α and TGFβ1 to the pathogenesis of autoimmune-associated congenital heart block. J Immunol 171: 3253-3261
28. Clancy RM et al. (2007) Role of hypoxia and cAMP in the transdifferentiation of human fetal cardiac fibroblasts: Implications for progression to scarring in autoimmune-associated congenital heart block. Arthritis Rheum 56: 4120-4131
29. McCue CM et al. (1977) Congenital heart block in newborns of mothers with connective tissue disease. Circulation 56: 82-90
30. Geggel RL et al. (1988) Postnatal progression from second- to third-degree heart block in neonatal lupus syndrome. J Ped 113 1049-1052
31. Askanase AD et al. (2002) Spectrum and progression of conduction abnormalities in infants born to mothers with anti-Ro/La antibodies. Lupus 11: 145-151
32. Saleeb S et al. (1999) Comparison of trealment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block. Arthritis Rheum 42: 2335-2345
33. Jaeggi ET et al. (2004) Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 110: 1542-1548
34. Rosenthal D et al. (1998) A new therapeutic approach to the fetus with congenital complete heart block: Pre-emptive, targeted therapy with dexamethasone. Obstet Gynecol 92: 689-691
35. Breur JMPJ et al. (2004) Treatment of fetal heart block with maternal steroid therapy: Case report and review of the fiterature. Ultrasound Obstet Gynecol 24: 467-472
36. Brucato A et al. (2006) Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero. Ann Rheum Dis 65 1422-1426
37. Airo P et al. (2006) Characterization of T-cell population in children with prolonged fetal exposure to dexamethasone for anti-Ro/SS-A antibodies associated congenital heart block. Lupus 15: 553-561.
38. Sonesson SE et al. (2004) Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52 kD antibodies. Arthritis Rheum 50: 1253-1261
39. Andelfinger G et al. (2001) Reference values for time intervals between atrial and ventricular contractions of the fetal heart measured by two Doppler techniques. Am J Cardiol 88: 1433-1436
40. Clancy RM et al. (2002) Transdifferentiation of cardiac fibroblasts, a fetal factor in anti-SSA/Ro-SSB/La antibody-mediated congenital heart block. J Immunol 169: 2156-2163
41. Kaaja R and Julkunen H (2003) Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al., [letter]. Arthritis Rheum 48: 281-282
42. Looney RJ and Huggins J (2006) Use of intravenous immunoglobulin (IVIG). Best Proof Res Clin Haematol 18: 3-25
43. Samuelsson A et al. (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291: 445-446
44. Nimmerjahn F and Ravetch JV (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 26: 513-533
45. Anthony RM et al. (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320: 373-376
46. Preventive IVIG Therapy for Congenital Heart Block (PITCH) [http://clinicaltrials.gov/ct2/show/NCTOO460928?term= NCT00460928&rank=1] (accessed, 13 January 2009)